



16 July 2021
EMA/CVMP/378788/2021
Committee for Medicinal Products for Veterinary Use

MRL summary opinion¹

Bambermycin

Poultry

On 15 July 2021 the Committee for Medicinal Products for Veterinary Use adopted an opinion² recommending the inclusion of bambermycin in poultry in Table 1 (allowed substances) of the Annex to Commission Regulation (EU) No 37/2010 of 22 December 2009, in accordance with the following table:

Pharmacologically active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions	Therapeutic classification
Bambermycin	Flavophospholipol A	Poultry	100 µg/kg 100 µg/kg 3000 µg/kg 20000 µg/kg	Muscle Skin and fat in natural proportions Liver Kidney	Not for use in animals from which eggs are produced for human consumption	Anti-infectious agents / Antibiotics

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may request re-examination of any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to request such re-examination within 15 days of receipt of the opinion

